Recently prospective studies on the impact of IL-17 inhibitors on cardiovascular risk are ongoing such as Vascular Inflammation in Psoriasis (VIP) trials of secukinumab (VIP‐S; NCT02690701), which is evaluating the cardiovascular risk in psoriasis patients from many aspects, including aortic inflammation and cardiometabolic biomarkers. Here, IL17A is linked to psoriasis.